Form 4: NextCure CFO Granted 14,670 Stock Options

NextCure's Chief Financial Officer, Steven P. Cobourn, was granted 14,670 employee stock options with a vesting schedule extending to 2027 and beyond.

Summary

• Steven P. Cobourn, Chief Financial Officer of NextCure, Inc. (NXTC), was granted 14,670 employee stock options.
• The options have an exercise price of $10.85 per share.
• The transaction date for the grant was January 30, 2026.
• One-fourth of the granted options will vest on January 30, 2027.
• The remaining options will vest in 36 equal monthly installments, commencing on February 28, 2027.
• The expiration date for these options is January 29, 2036.
• Following this transaction, Mr. Cobourn beneficially owns 14,670 derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, though it introduces potential future dilution.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of the shareholders, incentivizing long-term company performance.
• This compensation structure can aid in the retention of key executive talent, ensuring continuity in leadership.

Negatives

• The future exercise of these options could lead to a degree of share dilution for existing shareholders.

Future Outlook

The vesting schedule for the granted options extends through January 2027, with monthly installments continuing for 36 months thereafter, indicating a long-term incentive structure for the Chief Financial Officer.

Industry Context

StockSavvy.ai notes that stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical sectors, often used to attract and retain talent while aligning executive incentives with long-term shareholder value creation. This grant to NextCure's CFO is consistent with typical industry practices for executive compensation.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard compensation practice across the biotechnology industry, comparable to grants observed at companies like Moderna, BioNTech, or Regeneron, which frequently use equity-based incentives to motivate and retain key executives.
• The vesting schedule, with an initial cliff vesting followed by monthly installments, is a common structure designed to ensure long-term commitment and performance, similar to those seen in many high-growth tech and biotech firms.

Related Party Transactions

• None beyond the disclosed compensation event for the Chief Financial Officer, which is a standard insider transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also increased alignment of executive interests with long-term stock performance.
• Employees (CFO): Receives a significant equity incentive, tying personal wealth to company success and providing a retention mechanism.

Next Steps

• One-fourth of the options will vest on January 30, 2027.
• The remaining options will vest in 36 monthly installments starting February 28, 2027.

Key Dates

Keywords

NextCure, NXTC, Stock Options, Insider Transaction, CFO Compensation, Employee Stock Option, Vesting Schedule, Biotechnology, Pharmaceuticals